In December 2019, patients with respiratory symptoms attended some medical institutions in Wuhan, China, and were subsequently diagnosed with a new type of coronavirus pneumonia. In February 2020, WHO considered the disease as a Public Health Emergency, a pandemic known as Corona Virus Disease 2019 (CoVid-19). In this sense, this article aims to demonstrate findings in the literature that corroborate the use of chloroquine / hydroxychloroquine in the clinical management of CoVid-19. This is a bibliographic review, in which the following reference databases were used: Virtual Health Library (Bvs), Web of Science; Capes Journal; SciELO; PubMed and LILACS. The critical evaluation of the articles selected for writing the article was performed using the Critical Appraisal Tool (CAT). In turn, it is understood that chloroquine / hydroxychloroquine can inhibit the replication of several viruses, interacting with the viral input mediated by endossoma or with the final stages of viruses replication involved. In addition, the use of Chloroquine concomitant with remdesivir may have promising outcomes until a vaccine can be developed. Therefore, chloroquine / hydroxychloroquine has immunomodular properties that may be of interest in viral infections associated with inflammation and/or immune activation, requiring additional research, always considering its potential for toxicity to the human body.